Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces that it has drawn down the remaining €10 million available under its unsecured €25 million loan facility with Cosm...
GLOBENEWSWIRE
READ MORE
|
Alexion has made no secret of its plan to diversify beyond its blockbuster rare disease franchise. Now, the company has taken a flier out on a disappointing drug that targets severe bleeding—and it's hoping to parlay its hospital contacts into a sales boost that'll appease unruly investors. Alexion agreed to buy Portola Pharmaceuticals and its sole approved medicine, anticoagulant reversal agent Andexxa, in a deal valued at around $1.4 billion, the drugmakers said Monday. That'...
FIERCEPHARMA
READ MORE
|
Scientists are hailing what they say could be a "new era of therapeutics" using anti-inflammatory injections to lower the risk of heart attacks. Heart attack survivors given injections of a targeted anti-inflammatory drug called canakinumab had fewer attacks in the future, scientists writing in the New England Journal of Medicine* say. Cancer deaths were also halved in those treated with the drug, which is normally used only for rare inflammatory conditions....
READ MORE
|
Antibe Therapeutics has signed a licensing and distribution agreement with Laboratoires Acbel for the drug ATB-346 in Greece, Romania, Serbia, Bulgaria, Albania, Algeria and Jordan. Anti-inflammatory drug ATB-346 has been designed to spare the gastrointestinal tract of the ulcers and bleeding normally associated with non-steroidal anti-inflammatory drugs (NSAIDs)....
READ MORE
|
The FDA raised a red flag Monday on Pfizer's immunology drug Xeljanz after study data drew potential links between its higher, 10mg dose and life-threatening or fatal blood clots. In a safety communication, the agency highlighted Pfizer's decision last week to move rheumatoid arthritis trial patients taking 10mg of Xeljanz twice daily to the twice-daily 5mg dose. Early data from that trial suggested that patients on the higher dose were more likely to suffer pulmonary embolism—bloo...
READ MORE
|
Eli Lilly has filed a new migraine drug, lasmiditan, with the US regulator, the first drug in its class to be reviewed as a treatment for the condition. The US pharma added that the regulator has granted its Emgality (galcanezumab) Breakthrough Designation for prevention of episodic cluster headache, building on a previous approval in another form of migraine. An oral drug, lasmiditan is a selective serotonin 5-HT1F agonist that Lilly says is distinct from other approved migraine therapies and d...
READ MORE
|